Exercise Training Improves Tumor Control by Increasing CD8+ T-cell Infiltration via CXCR3 Signaling and Sensitizes Breast Cancer to Immune Checkpoint Blockade
Igor L Gomes-Santos,Zohreh Amoozgar,Ashwin S Kumar,William W Ho,Kangsan Roh,Nilesh P Talele,Hannah Curtis,Kosuke Kawaguchi,Rakesh K Jain,Dai Fukumura,Igor L. Gomes-Santos,Ashwin S. Kumar,William W. Ho,Nilesh P. Talele,Rakesh K. Jain
DOI: https://doi.org/10.1158/2326-6066.CIR-20-0499
IF: 10.1
2021-07-03
Cancer Immunology Research
Abstract:The mechanisms behind the antitumor effects of exercise training (ExTr) are not fully understood. Using mouse models of established breast cancer, we examined here the causal role of CD8 + T cells in the benefit acquired from ExTr in tumor control, as well as the ability of ExTr to improve immunotherapy responses. We implanted E0771, EMT6, MMTV-PyMT, and MCa-M3C breast cancer cells orthotopically in wild-type or Cxcr3 –/– female mice and initiated intensity-controlled ExTr sessions when tumors reached approximately 100 mm 3 . We characterized the tumor microenvironment (TME) using flow cytometry, transcriptome analysis, proteome array, ELISA, and immunohistochemistry. We used antibodies against CD8 + T cells for cell depletion. Treatment with immune checkpoint blockade (ICB) consisted of anti–PD-1 alone or in combination with anti–CTLA-4. ExTr delayed tumor growth and induced vessel normalization, demonstrated by increased pericyte coverage and perfusion and by decreased hypoxia. ExTr boosted CD8 + T-cell infiltration, with enhanced effector function. CD8 + T-cell depletion prevented the antitumor effect of ExTr. The recruitment of CD8 + T cells and the antitumor effects of ExTr were abrogated in Cxcr3 –/– mice, supporting the causal role of the CXCL9/CXCL11–CXCR3 pathway. ExTr also sensitized ICB-refractory breast cancers to treatment. Our results indicate that ExTr can normalize the tumor vasculature, reprogram the immune TME, and enhance the antitumor activity mediated by CD8 + T cells via CXCR3, boosting ICB responses. Our findings and mechanistic insights provide a rationale for the clinical translation of ExTr to improve immunotherapy of breast cancer.
oncology,immunology